Top

Cancer Immunology, Immunotherapy

Published in:

01-03-2017 | Original Article

Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma

Authors: Yingming Zhu, Minghuan Li, Cong Bo, Xuemei Liu, Jianbo Zhang, Zhenxiang Li, Fen Zhao, Li Kong, Jinming Yu

Published in: Cancer Immunology, Immunotherapy | Issue 3/2017

Abstract

Purpose

We assessed the prognostic significance of, and the relationship between, the pretreatment lymphocyte-to-monocyte ratio (LMR) and the TILs/tumor-associated macrophages (TAMs) ratio, in patients with esophageal squamous cell carcinoma (ESCC) of pathological stage T3N0M0 (pT3N0M0).

Methods

A total of 220 newly diagnosed ESCC patients of stage pT3N0M0 who had not undergone neoadjuvant therapy were included. Densities of CD8+ TILs, CD4+ TILs, CD45RO+ TILs, and CD68+ TAMs were assessed by immunohistochemical staining of tissue microarray cores from all 220 pT3N0M0 ESCC patients (who underwent radical resection). Hematological biomarkers including lymphocyte and monocyte counts were obtained from routine preoperative blood test data, and the LMR and TILs/TAMs ratios calculated. Cutoff finder for survival prediction was plotted to find out the optimal cutoff point for each parameter.

Results

The LMR and TILs/TAMs ratios were interrelated. On univariate analyses of data from the entire cohort, the LMR, CD45RO/CD68 ratio, and CD8/CD68 ratio were significantly associated with both OS and disease-free survival. Only the CD45RO/CD68 ratio was independently prognostic of survival on multivariate analysis.

Conclusions

The prognostic significance of the CD45RO/CD68 ratio was higher than that of the LMR. The CD45RO/CD68 ratio is a useful independent prognostic marker in patients with pT3N0M0 ESCC who have undergone complete resection without neoadjuvant therapy.

Available only for authorised users

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K (2004) Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 198(2):205–211. doi:10.1016/j.jamcollsurg.2003.10.005 CrossRefPubMed

Rice TW, Blackstone EH, Rusch VW (2010) 7th edition of the AJCC cancer Staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 17(7):1721–1724. doi:10.1245/s10434-010-1024-1 CrossRefPubMed

Kim J, Bae JS (2016) Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm 2016:6058147. doi:10.1155/2016/6058147

Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63(7):1555–1559PubMed

Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y (2015) Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41(10):971–978. doi:10.1016/j.ctrv.2015.10.003 CrossRefPubMed

Gu L, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X (2016) Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget 7(22):31926–31942. doi:10.18632/oncotarget.7876 PubMedPubMedCentral

Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ (2016) The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. doi:10.1097/sla.0000000000001743 PubMedCentral

Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12):e51862. doi:10.1371/journal.pone.0051862 CrossRefPubMedPubMedCentral

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TWG (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271. doi:10.1093/annonc/mdu450 CrossRefPubMed

10.

Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, Zhang B, Kalinski P, Zhang Y (2015) CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer 113(5):747–755. doi:10.1038/bjc.2015.290 CrossRefPubMedPubMedCentral

11.

Dutta S, Going JJ, Crumley AB, Mohammed Z, Orange C, Edwards J, Fullarton GM, Horgan PG, McMillan DC (2012) The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 106(4):702–710. doi:10.1038/bjc.2011.610 CrossRefPubMedPubMedCentral

12.

Crumley AB, Going JJ, Hilmy M, Dutta S, Tannahill C, McKernan M, Edwards J, Stuart RC, McMillan DC (2011) Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Ann Surg Oncol 18(9):2604–2612. doi:10.1245/s10434-011-1658-7 CrossRefPubMed

13.

Tao CJ, Chen YY, Jiang F, Feng XL, Jin QF, Jin T, Piao YF, Chen XZ (2016) A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy. Oncotarget. doi:10.18632/oncotarget.9695

14.

Farber DL, Yudanin NA, Restifo NP (2014) Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 14(1):24–35. doi:10.1038/nri3567 CrossRefPubMed

15.

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. doi:10.1038/nrc3245 CrossRefPubMed

16.

Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M, Nakajima Y (2012) Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 168(2):186–191. doi:10.1111/j.1365-2249.2012.04565.x CrossRefPubMedPubMedCentral

17.

Rauser S, Langer R, Tschernitz S, Gais P, Jutting U, Feith M, Hofler H, Walch A (2010) High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I–IIA) esophageal adenocarcinoma. BMC Cancer 10:608. doi:10.1186/1471-2407-10-608 CrossRefPubMedPubMedCentral

18.

Paulsen EE, Kilvaer T, Khanehkenari MR, Maurseth RJ, Al-Saad S, Hald SM, Al-Shibli K, Andersen S, Richardsen E, Busund LT, Bremnes R, Donnem T (2015) CD45RO(+) memory T lymphocytes—a candidate marker for TNM-immunoscore in squamous non-small cell lung cancer. Neoplasia 17(11):839–848. doi:10.1016/j.neo.2015.11.004 CrossRefPubMedPubMedCentral

19.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. doi:10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentral

20.

Lin R, Zhang C, Zheng J, Tian D, Lei Z, Chen D, Xu Z, Su M (2016) Chronic inflammation-associated genomic instability paves the way for human esophageal carcinogenesis. Oncotarget 7(17):24564–24571PubMedPubMedCentral

21.

Hutterer GC, Pichler M, Chromecki TF, Strini KA, Klatte T, Pummer K, Remzi M, Mannweiler S, Zigeuner R (2013) Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology 63(3):309–315. doi:10.1111/his.12163 CrossRefPubMed

22.

Hu Y, He MY, Zhu LF, Yang CC, Zhou ML, Wang Q, Zhang W, Zheng YY, Wang DM, Xu ZQ, Wu YN, Liu LK (2016) Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res 35:12. doi:10.1186/s13046-015-0281-z CrossRefPubMedPubMedCentral

23.

Sugimura K, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y (2015) High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol 111(6):752–759. doi:10.1002/jso.23881 CrossRefPubMed

24.

Guo SJ, Lin DM, Li J, Liu RZ, Zhou CX, Wang DM, Ma WB, Zhang YH, Zhang SR (2007) Tumor-associated macrophages and CD3-zeta expression of tumor-infiltrating lymphocytes in human esophageal squamous-cell carcinoma. Dis Esophagus 20(2):107–116. doi:10.1111/j.1442-2050.2007.00655.x CrossRef

25.

Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61. doi:10.1016/j.immuni.2014.06.010 CrossRefPubMedPubMedCentral

26.

Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. doi:10.1016/j.cell.2010.03.014 CrossRefPubMedPubMedCentral

27.

Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11–18. doi:10.1016/j.bbcan.2009.02.004 PubMed

28.

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 + T cells. J Clin Investig 116(10):2777–2790. doi:10.1172/JCI28828 CrossRefPubMedPubMedCentral

29.

Han L, Jia Y, Song Q, Wang N, Wang J, Bai B, Chen X, Wang C, Cheng Y (2016) Prognostic significance of preoperative absolute peripheral monocyte count in esophageal squamous cell carcinoma. Dis Esophagus 29(7):740–746. doi:10.1111/dote.12401 CrossRefPubMed

30.

Huang Y, Feng JF (2015) Low preoperative lymphocyte to monocyte ratio predicts poor cancer-specific survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther 8:137–145. doi:10.2147/OTT.S73794 PubMedPubMedCentral

31.

Ji H, Xuan Q, Yan C, Liu T, Nanding A, Zhang Q (2016) The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy. Oncotarget 7(23):34881–34889. doi:10.18632/oncotarget.8993 PubMedPubMedCentral

32.

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, Trajanoski S, Stojakovic T, Eberhard K, Leithner A, Pichler M (2014) The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 135(2):362–370. doi:10.1002/ijc.28677 CrossRefPubMed

33.

Liao R, Jiang N, Tang ZW, Li DW, Huang P, Luo SQ, Gong JP, Du CY (2016) Systemic and intratumoral balances between monocytes/macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery. Oncotarget 7(21):30951–30961PubMedPubMedCentral

34.

Xiao WW, Zhang LN, You KY, Huang R, Yu X, Ding PR, Gao YH (2015) A low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in pathological T3N0 rectal cancer patients following total mesorectal excision. J Cancer 6(7):616–622. doi:10.7150/jca.11727 CrossRefPubMedPubMedCentral

35.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi:10.1038/nature07205 CrossRefPubMed

36.

Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6(3):1670–1690. doi:10.3390/cancers6031670 CrossRef

37.

Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A, Kastenberger M, Brockhoff G, Andreesen R, Kreutz M (2008) Expression of CD68 in non-myeloid cell types. Scand J Immunol 67(5):453–463. doi:10.1111/j.1365-3083.2008.02091.x CrossRefPubMed

38.

Ling A, Edin S, Wikberg ML, Oberg A, Palmqvist R (2014) The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 110(10):2551–2559. doi:10.1038/bjc.2014.161 CrossRefPubMedPubMedCentral

39.

Jia Y, Zeng Z, Li Y, Li Z, Jin L, Zhang Z, Wang L, Wang FS (2015) Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS ONE 10(2):e0117458. doi:10.1371/journal.pone.0117458 CrossRefPubMedPubMedCentral

40.

Xu T, Huang Z, Su B, Wang S, Wang D, Wang C, Wei W, Jiang J, Zhang G, Yang H, Hu W (2014) Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma. Med oncol. doi:10.1007/s12032-014-0198-y

41.

Ordonez R, Henriquez-Hernandez LA, Federico M, Valenciano A, Pinar B, Lloret M, Bordon E, Rodriguez-Gallego C, Lara PC (2014) Radio-induced apoptosis of peripheral blood CD8 T lymphocytes is a novel prognostic factor for survival in cervical carcinoma patients. Strahlenther Onkol 190(2):210–216. doi:10.1007/s00066-013-0488-x CrossRefPubMed

42.

Turksma AW, Bontkes HJ, van den Heuvel H, de Gruijl TD, von Blomberg BME, Braakhuis BJM, Leemans CR, Bloemena E, Meijer C, Hooijberg E (2013) Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 19(6):577–584. doi:10.1111/odi.12037 CrossRefPubMed

43.

Halec G, Schmitt M, Egger S, Abnet CC, Babb C, Dawsey SM, Flechtenmacher C, Gheit T, Hale M, Holzinger D, Malekzadeh R, Taylor PR, Tommasino M, Urban MI, Waterboer T, Pawlita M, Sitas F (2016) Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis. Int J Cancer 139(1):85–98. doi:10.1002/ijc.29911 CrossRefPubMed

Title: Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma
Authors: Yingming Zhu
Minghuan Li
Cong Bo
Xuemei Liu
Jianbo Zhang
Zhenxiang Li
Fen Zhao
Li Kong
Jinming Yu
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 3/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1931-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

RETRACTED ARTICLE: Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells

Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro

T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer

Preventive DNA vaccination against CEA-expressing tumors with anti-idiotypic scFv6.C4 DNA in CEA-expressing transgenic mice

Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment

Acknowledgement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer